Bottom line: An anti-inflammatory research peptide for gut and skin, promising in mice but barely tested in people. Genuinely experimental.
Safety at a glance
- Status: Not FDA-approved; research peptide. Almost entirely preclinical.
- Evidence: Almost entirely preclinical (cells + animals).
- Do not use if: you are unsure - human evidence is minimal; clear it with a doctor.
- Not medical advice - decide this with a licensed physician.
What it does - plain English
KPV is one of the smallest peptides people use - just three amino acids (lysine, proline, valine). It's the tail end of a larger hormone called alpha-MSH, and it carries that hormone's anti-inflammatory punch without the part that makes skin tan or pigment.
In cell and animal studies, KPV dials down the body's inflammation machinery - it quiets the signaling pathways (NF-kB and inflammatory messengers like TNF-alpha and IL-6) that drive swelling, irritation, and tissue damage. Because it's small and stable, it can get into cells directly, and a gut transporter (PepT1) lets it act locally on an inflamed intestinal lining.
That's why it gets discussed for gut conditions like inflammatory bowel disease, for skin problems like eczema and psoriasis, and for wound healing. It is frequently paired with BPC-157 in gut-repair stacks.
Status
Watch. The mechanism is the strong part; the evidence is the weak part. KPV has a clean, well-described anti-inflammatory mechanism, and the early laboratory work is genuinely promising - reduced colon inflammation in mouse models of colitis, calmer skin in animal studies.
But that's where it stops. The evidence is almost entirely preclinical: cells and rodents, not human trials. There are no large controlled studies in people telling you a dose, a duration, or a real-world success rate. This is the thinnest evidence base of our recent additions, which is exactly why it sits in Watch and not higher.
Legal status
KPV is not FDA-approved for human use and is not on the banned list. It lives in the same "research chemicals" gray zone as most peptides on this list, sold by research vendors as "for research purposes only, not for human consumption." It shows up in oral capsule, topical, and injectable forms.
What that means in practice: there is no regulated product, no standardized dose, and no consumer protection. If you pursue it, a Certificate of Analysis (COA - the lab report proving the vial contains what it claims) is the floor, not a nice-to-have. No COA, no buy.
Side effects and the honest caveat
KPV is generally described as well-tolerated in the limited research available - mild injection-site irritation, occasional digestive upset at higher oral doses. But "well-tolerated in limited research" is not the same as "proven safe in people over time." The real caveat is the absence of human data, not a scary side-effect list. You'd be running an experiment on yourself with a peptide that has never been through a real human trial.
New to peptides? Start with the foundations ->
The research worth knowing
The gut-inflammation mechanism
PubMed - KPV, PepT1, and intestinal inflammation
The body of preclinical work showing that KPV is taken up by the gut's PepT1 transporter and reduces colonic inflammation in mouse models of colitis. This is the strongest part of the KPV story - and it is still animal and cell research, not human trials.
The alpha-MSH anti-inflammatory lineage
PubMed - KPV and the alpha-MSH anti-inflammatory pathway
Background on why KPV works: it's the active anti-inflammatory fragment of alpha-MSH, so it inherits the parent hormone's ability to calm NF-kB signaling without the pigmentation effect. Read this to understand the mechanism; don't read it as proof of a human benefit.
Last reviewed · 2026·06·04 · Status reviewed weekly